Barcelona [Barcelona]

我们是谁

  • 1 月 9, 2024
    A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator’s Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) ( CheckMate 8HW )
  • 1 月 9, 2024
    A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer ( SEAMARK )
  • 4 月 5, 2022
    BMS-986253与Nivolumab或Nivolumab加Ipilimumab联合治疗晚期癌症的研究
  • 4 月 5, 2022
    BMS-986288单独或与Nivolumab联合治疗晚期实体瘤的免疫疗法研究
  • 4 月 5, 2022
    一项针对晚期实体瘤患者的BMS-986340单药及与Nivolumab联合用药研究